The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
The telomere length and subtelomeric methylated status of peripheral blood leukocytes has been reported to be correlated with many kinds of pathophysiological conditions. However, the correlation between the telomeric parameters and clinical laboratory data in metabolic disorders is not well known. This study investigated the correlation between the telomere length and subtelomeric methylated status in peripheral leukocytes and the laboratory data of male outpatients with combined metabolic disorders and no clinical history of cardiovascular or cerebrovascular event were assessed, to find good clinical laboratory markers reflecting the biological aging. The laboratory data were collected in 26 Japanese male outpatients with diabetes mellitus and hyperlipidemia, and no history of cardiovascular or cerebrovascular event, and the telomeric parameters in their peripheral leukocytes were determined by Southern blot with methylation-sensitive and insensitive isoschizomers. Any correlations between the laboratory data and the telomeric parameters were assessed. The patients showed a significant negative correlation among the bilirubin and creatine phosphokinase with the aging-associate change of the telomeric and subtelomeric parameters. Lowered serum bilirubin and creatinine phosphokinase level correlated to genomic aging represented by telomere attrition of patients with metabolic disorders.
Maeda
Toyoki
T
The Division of Molecular and Clinical Gerontology, The Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, 874-0838, Japan. maedat@beppu.kyushu-u.ac.jp
Oyama
Jun-ichi
J
Higuchi
Yoshihiro
Y
Koyanagi
Masamichi
M
Sasaki
Makoto
M
Arima
Takahiro
T
Mimori
Koshi
K
Makino
Naoki
N
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D001663:Bilirubin / Q000032:analysis / Q000097:blood; D019411:Clinical Laboratory Techniques / Q000706:statistics & numerical data*; D003402:Creatine Kinase / Q000032:analysis / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D007962:Leukocytes; D008297:Male; D008875:Middle Aged; D010045:Outpatients / Q000706:statistics & numerical data; D012150:Polymorphism, Restriction Fragment Length / Q000235:genetics; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D016615:Telomere / Q000235:genetics*
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride; D003402:Creatine Kinase; D001663:Bilirubin; D011345:Fenofibrate